ArticleBlood2012
Darwinian evolution and tiding clones in multiple myeloma.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.Blood cancer journal · 2020Trial
- Recent Advances and Challenges in Cancer Care, with a Focus on Multiple Myeloma, Lymphoma, and Lung Cancer: Key Insights from the Onco Summit 2024-The APAC Chapter.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Review
- Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.BMC medical genomics · 2025Article
- New horizons in our understanding of precursor multiple myeloma and early interception.Nature reviews. Cancer · 2024Review
- Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.Cancers · 2024Article
- Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.Biomedicines · 2023Review
- Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.Hematology reports · 2023Review
- Liquid biopsy in hematological malignancies: current and future applications.Frontiers in oncology · 2023Review
- Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine-Are We There Yet?International journal of molecular sciences · 2022Review
- Review
- Review
- Review
- Review
- Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.Frontiers in immunology · 2021Review
- Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.Cytometry. Part B, Clinical cytometry · 2020Article
- A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche.Journal of oncology · 2020Review
- Targeted Therapy With Immunoconjugates for Multiple Myeloma.Frontiers in immunology · 2020Review
- A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?Clinical case reports · 2019Article
- The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.International journal of molecular sciences · 2019Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Blood, Keats et al,(1) Egan et al,(2) and Walker et al(3) provide a genome-wide snapshot of the clonal landscape in multiple myeloma(MM)illustrating the complexity of the evolutionary process and the dynamics of clonal evolution over time.
Indexed as
Identifiers
22859708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.